Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 4,249 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Healthy
Interventions: Control digestible carbohydrate, Test resistant starch type 4; Other
Lead sponsor: Cargill; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Peripheral Artery Disease
Interventions: Stellarex 0.035" OTW Drug-coated Angioplasty Balloon, EverCross™ 0.035 PTA Balloon Catheter; Device
Lead sponsor: Spectranetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 39
States / cities: Yuma, Arizona • Fremont, California • Los Angeles, California + 34 more

Conditions: Extreme Prematurity
Interventions: Epo, Control; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 24 Weeks to 27 Weeks
Enrollment: 941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 19
States / cities: Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 14 more

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Blood Glucose, Blood Insulin
Interventions: Fruit snack 1, Fruit snack 2, Fruit snack 3, Fruit snack 4, Fruit snack 5, Confection control; Dietary Supplement
Lead sponsor: Ocean Spray Cranberries, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Ventral Hernia, Ventral Hernia Repair, Postoperative Pain
Interventions: Bupivicaine, Fentanyl, Thoracic epidural analgesia, Hydromorphone, Acetaminophen, Ketorolac, magnesium sulfate, Tramadol, Gabapentin, Cyclobenzaprine, transversus abdominis plane block; Drug · Device · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Muscle Soreness
Interventions: Diclofenac sodium gel 1%, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Rett Syndrome
Interventions: Trofinetide, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 5 Years to 20 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more

Conditions: Chronic Kidney Disease, Kidney Disease
Interventions: MK-0677, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Thyroid Cancer
Interventions: Lenvatinib, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 38
States / cities: Little Rock, Arkansas • La Jolla, California • Los Gatos, California + 30 more

Conditions: Sexually Transmitted Infections, HIV Infections
Interventions: Experimental; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Torrance, California

Conditions: Hypertension
Interventions: Febuxostat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Foley, Alabama • Buena Park, California • Carmichael, California + 42 more

Conditions: Anthrax
Interventions: Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim; Drug · Other
Lead sponsor: PharmAthene, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Benign Prostatic Hyperplasia
Interventions: Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo; Drug · Other
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 15
States / cities: Anniston, Alabama • Lincoln, California • Sacramento, California + 12 more

Conditions: Food Habits
Interventions: Glucotrojan; Dietary Supplement
Lead sponsor: Tastermonial Inc; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cupertino, California

Conditions: Allergic Conjunctivitis
Interventions: contact lens with ketotifen, contact lens; Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 8 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Intraocular Lens Replacement
Interventions: OMS302, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more

Conditions: Acute Ischemic Stroke, Cerebral Stroke
Interventions: Drug: Normal Saline, Sovateltide; Drug
Lead sponsor: Pharmazz, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more

Conditions: Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Interventions: Pioglitazone, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Fibromyalgia
Interventions: DS-5565, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 22
States / cities: Phoenix, Arizona • Colton, California • Los Angeles, California + 19 more

Conditions: Polycystic Ovary Syndrome
Interventions: Elix Daily Harmony, Elix Cycle Balance; Other
Lead sponsor: Zenchi, Inc.; Industry
Eligibility: 18 Years to 36 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy Volunteers
Interventions: Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obesity
Interventions: BMF-650; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Trigeminal Neuralgia
Interventions: Carbon Dioxide Drug Delivery System (CDDS); Drug
Lead sponsor: Capnia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Tampa, Florida • New York, New York + 3 more

Search by objective public record fields.

A Randomized, Controlled, Crossover Study to Assess the Glucose and Insulin Excursions of a Test Fiber

ILLUMENATE Pivotal Post-Approval Study (PAS)

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

Monitoring Postprandial Blood Glucose and Insulin in Fruit Snacks

Epidural Analgesia Versus Opioid-sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdominis Release

A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)

Effect of Febuxostat on Blood Pressure

Ph1 Study of Valortim and Ciprofloxacin in Humans

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

Real-world Evaluation of JBA GlucoTrojan With Reducose® on Glycemic Response

Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

A Study to Evaluate the Effect of Elix Cycle Balance and Daily Harmony on Polycystic Ovary Syndrome

First Safety Study in Humans of a Single Dose of CPG 52364

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia